Package Leaflet: Information for the Patient
BACEQ 25 mg prolonged-release injectable suspension EFG
BACEQ 50 mg prolonged-release injectable suspension EFG
BACEQ 75 mg prolonged-release injectable suspension EFG
BACEQ 100 mg prolonged-release injectable suspension EFG
BACEQ 150 mg prolonged-release injectable suspension EFG
Initial Treatment Pack:
BACEQ 150 mg and BACEQ 100 mg prolonged-release injectable suspension EFG
Read the entire package leaflet carefully before starting to use this medication, as it contains important information for you.
Keep this package leaflet, as you may need to read it again.
Contents of the Package Leaflet
BACEQ contains the active substance paliperidone, which belongs to the class of antipsychotic medications, and is used as maintenance treatment for the symptoms of schizophrenia in adult patients stabilized with paliperidone or risperidone.
If you have shown a response to paliperidone or risperidone in the past and have mild or moderate symptoms, your doctor may initiate treatment with BACEQ without prior stabilization with paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive means an excess of symptoms that are not normally present. For example, a person with schizophrenia may hear voices or see things that do not exist (called hallucinations), have false beliefs (called delusions), or have excessive distrust of others. Negative refers to the lack of behaviors or feelings that are normally present. For example, a person with schizophrenia may withdraw into themselves and not respond to any emotional stimuli or may have difficulty speaking in a clear and logical manner. People with this disorder may also feel depressed, anxious, guilty, or tense.
BACEQ can help alleviate the symptoms of your illness and prevent them from recurring.
Do not usepaliperidone
Warnings and Precautions
Consult your doctor, pharmacist, or nurse before starting to use BACEQ.
This medication has not been studied in elderly patients with dementia. However, elderly patients with dementia who are being treated with similar medications may have an increased risk of stroke or death (see section 4, possible side effects).
All medications have side effects, and some of the side effects of this medication may worsen the symptoms of other conditions. For this reason, it is essential that you discuss with your doctor any of the following conditions that may worsen during treatment with this medication:
If you have any of these conditions, please consult your doctor, as it may be necessary to adjust your dose or monitor you for a period of time.
Because it has been rarely observed in patients treated with this medication that there is a dangerously low number of a type of white blood cells necessary to fight infections in the blood, your doctor may check your white blood cell count.
Even if you have previously tolerated oral paliperidone or risperidone, rare allergic reactions may occur after receiving paliperidone injections. Seek medical help immediately if you experience a skin rash, swelling of the throat, itching, or breathing problems, as these may be signs of a severe allergic reaction.
This medication may cause weight gain. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with this medication, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed. Your doctor should check for signs of increased blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
Since this medication can reduce the urge to vomit, there is a possibility that it may mask the body's normal response to ingesting toxic substances or other conditions.
During eye surgery for cataracts, the pupil (the black circle in the center of the eye) may not increase in size as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which can cause eye damage. If you are considering eye surgery, make sure to inform your ophthalmologist that you are using this medication.
Children and Adolescents
Do not use this medication in children under 18 years of age.
Other Medications and BACEQ
Inform your doctor if you are using, have recently used, or may need to use any other medication.
Taking this medication with carbamazepine (an antiepileptic and mood stabilizer) may require a change in your dose of this medication.
Since this medication acts primarily on the brain, interaction with other medications that also act on the brain may cause an exaggeration of side effects, such as drowsiness or other effects on the brain, such as other psychiatric medications, opioids, antihistamines, and sleep medications.
Since this medication can lower blood pressure, you should be careful when using this medication with other medications that also lower blood pressure.
This medication may reduce the effect of medications for Parkinson's disease and restless legs syndrome (e.g., levodopa).
This medication may cause an abnormality in the electrocardiogram (ECG) that shows that it is necessary for an extended period for an electrical impulse to travel through a certain part of the heart (known as "prolongation of the QT interval"). Other medications that have this effect include some medications used to treat heart rhythm or to treat infections, in addition to other antipsychotics.
If you are prone to seizures, this medication may increase your chances of experiencing them. Other medications that have this effect include some medications used to treat depression or to treat infections, in addition to other antipsychotics.
BACEQ should be used with caution with medications that increase the activity of the central nervous system (psychostimulants such as methylphenidate).
Using BACEQ with Alcohol
Alcohol should be avoided.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication. You should not use this medication during pregnancy unless you have discussed it with your doctor. The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last trimester of pregnancy (last three months of pregnancy): tremors, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, you should contact your doctor.
This medication may pass from mother to child through breast milk and may harm the baby. Therefore, you should not breastfeed while using this medication.
Driving and Using Machines
During treatment with this medication, dizziness, extreme fatigue, and vision problems (see section 4) may occur. This should be taken into account when maximum attention is required, e.g., when driving or operating machines.
BACEQ contains Sodium
This medication contains less than 1 mmol of sodium (23 mg) per dose; it is essentially "sodium-free".
Your doctor or another healthcare professional will administer this medication to you. Your doctor will tell you when to receive the next injection. It is essential that you do not miss any scheduled doses. If you cannot attend your appointment with the doctor, make sure to call them immediately to schedule another appointment as soon as possible.
You will receive the first injection (150 mg) and the second injection (100 mg) of this medication in the upper arm, approximately one week apart. From then on, you will receive an injection (of 25 mg to 150 mg) in the upper arm or buttocks once a month.
If your doctor is switching you from risperidone long-acting injection to this medication, you will receive the first injection of this medication (of 25 mg to 150 mg) in the upper arm or buttocks at the next scheduled injection. From then on, you will receive an injection (of 25 mg to 150 mg) in the upper arm or buttocks once a month.
Depending on your symptoms, the doctor may increase or decrease the amount of medication you receive at the time of the monthly scheduled injection.
Patient with Kidney Problems
Your doctor may adjust the dose of this medication according to your kidney function. If you have mild kidney problems, your doctor may give you a lower dose. You should not use this medication if you have moderate or severe kidney problems.
Elderly Patients
Your doctor may reduce the dose of this medication if your kidney function is decreased.
If you use more BACEQ than you should
You will receive this medication under medical supervision; it is therefore unlikely that you will receive an excessive dose.
Patient who have received an overdose of paliperidone may experience the following symptoms: drowsiness or sedation, rapid heart rate, low blood pressure, abnormalities in the electrocardiogram (heart tracing), or slow or abnormal movements of the face, body, arms, or legs.
If you stop using BACEQ
If you stop receiving your injections, the effects of the medication will be lost. You should not stop using this medication unless your doctor tells you to, as your symptoms may return.
If you have any further questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Tell your doctor immediately if:
The following adverse effects may occur:
Very common adverse effects: may affect more than 1 in 10 patients
Common adverse effects: may affect up to 1 in 10 patients
Uncommon adverse effects: may affect up to 1 in 100 patients
Rare adverse effects: may affect up to 1 in 1,000 patients
Frequency not known: cannot be estimated from the available data
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or nurse, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the pre-filled syringe and on the box after "CAD or EXP". The expiration date is the last day of the month indicated.
This medicine does not require any special storage conditions.
Medicines should not be thrown away through wastewater or household waste. Deposit the containers and medicines you no longer need in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.
BACEQ Composition
The active ingredient is paliperidone
Each BACEQ 25 mg prefilled syringe contains 39 mg of paliperidone palmitate in 0.25 ml.
Each BACEQ 50 mg prefilled syringe contains 78 mg of paliperidone palmitate in 0.5 ml.
Each BACEQ 75 mg prefilled syringe contains 117 mg of paliperidone palmitate in 0.75 ml.
Each BACEQ 100 mg prefilled syringe contains 156 mg of paliperidone palmitate in 1 ml.
Each BACEQ 150 mg prefilled syringe contains 234 mg of paliperidone palmitate in 1.5 ml
Initial Treatment Package:
Each BACEQ 100 mg prefilled syringe contains 156 mg of paliperidone palmitate in 1 ml.
Each BACEQ 150 mg prefilled syringe contains 234 mg of paliperidone palmitate in 1.5 ml
The other components are:
polysorbate 20
macrogol 4000
citric acid monohydrate
disodium phosphate
sodium dihydrogen phosphate monohydrate
sodium hydroxide (for pH adjustment)
water for injectable preparations
Product Appearance and Container Contents
BACEQ is a white to off-white prolonged-release injectable suspension, which comes in a prefilled syringe (prolonged-release injectable)
Each container contains 1 prefilled syringe and 2 needles.
Initial Treatment Package:
Each package contains 1 BACEQ 150 mg container and 1 BACEQ 100 mg container.
Only certain package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Teva Pharma, S.L.U.
C/ Anabel Segura, 11, Edificio Albatros B, 1ª planta,
Alcobendas, 28108, Madrid (Spain)
Manufacturer:
Actavis Group PTC ehf.
Dalsharun 1
IS-220 Hafnarfjordur
Iceland
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
Laboratorios Farmacéuticos ROVI, S.A.
Julián Camarillo, 35
28037 – Madrid – Spain
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
|
Date of the last revision of this leaflet:February 2024
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
This information is intended only for healthcare professionals and should be read in conjunction with the complete prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use. It should be visually inspected for any foreign particles before administration. Do not use the product if the syringe is not visually free of foreign particles.
The container contains a prefilled syringe and two safety needles (one 22-gauge, 1½-inch [38.1 mm x 0.72 mm] needle and one 23-gauge, 1-inch [25.4 mm x 0.64 mm] needle) for intramuscular injection. BACEQ is also available in a treatment initiation pack that contains two prefilled syringes (150 mg + 100 mg) and two additional safety needles.
The first initiation dose of BACEQ (150 mg) is administered on Day 1 in the DELTOID muscle using the needle for DELTOID injection. The second initiation dose of BACEQ (100 mg) is also administered in the DELTOID muscle one week later (Day 8) using the needle for DELTOID injection.
If a patient is switched from prolonged-release injectable risperidone to BACEQ, the first BACEQ injection (dose range of 25 mg to 150 mg) can be administered in the DELTOID muscle or the GLUTEAL muscle, using the appropriate needle for the injection site, at the time of the next scheduled injection.
Subsequently, monthly maintenance injections can be administered in either the DELTOID muscle or the GLUTEAL muscle using the appropriate needle for the injection site.
In the case of DELTOID injection, if the patient weighs <90 kg, use the 23-gauge, 1-inch (25.4 mm x 0.64 mm) needle (needle with a blue hub); if patient weighs ≥ 90 22-gauge, 1½-inch (38.1 0.72 gray hub).< p>
In the case of GLUTEAL injection, use the 22-gauge, 1½-inch (38.1 mm x 0.72 mm) needle (needle with a gray hub).
8.a
8b
8c
Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.